Sakar Healthcare Ltd's Q3FY25 Quarter Results
- 18 Feb 2025
Result Summary
- Sakar Healthcare Ltd reported a 1.3% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a growth of 16.7%.
- Its expenses for the quarter were up by 0.4% QoQ and 10.9% YoY.
- The net profit decreased 5.6% QoQ and increased 118.8% YoY.
- The earnings per share (EPS) of Sakar Healthcare Ltd stood at 2.1 during Q3FY25.
Financial Statments for Q3FY25
| (₹ crores) | Q3FY25 | Q2FY25 | Q3FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 43.71 | 43.15 | 37.46 | 1.3% | 16.7% |
Total Expenses | 38.19 | 38.04 | 34.45 | 0.4% | 10.9% |
Profit Before Tax | 5.48 | 5.11 | 3.00 | 7.2% | 82.7% |
Tax | 0.94 | 0.31 | 0.93 | 203.2% | 1.1% |
Profit After Tax | 4.53 | 4.80 | 2.07 | -5.6% | 118.8% |
Earnings Per Share | 2.10 | 2.20 | 1.00 | -4.5% | 110.0% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Sakar Healthcare Ltd operates primarily in the pharmaceutical industry, focusing on manufacturing and marketing a range of pharmaceutical formulations. The company's portfolio includes a variety of therapeutic areas such as antibiotics, anti-inflammatory, cardiovascular, and gastroenterological medications, among others. Sakar Healthcare is based in India and serves both domestic and international markets. The company is committed to providing high-quality healthcare products and has been expanding its manufacturing capacity to cater to increasing demand. While specific recent developments are not detailed in the provided data, the company is likely involved in ongoing efforts to enhance its product offerings and market reach.
Revenue
In the third quarter of the fiscal year 2025 (Q3FY25), Sakar Healthcare Ltd reported a total income of ₹43.71 crores. This represents a slight increase of 1.3% compared to the previous quarter (Q2FY25), where total income stood at ₹43.15 crores. Year-over-year, the company saw a significant increase in total income by 16.7% from ₹37.46 crores in Q3FY24. The consistent growth in revenue suggests a positive trajectory for Sakar Healthcare's business operations, reflecting its capability to generate increased sales and potentially expand its market presence.
Profitability
Sakar Healthcare Ltd's profitability metrics indicate a robust performance. In Q3FY25, the company's profit before tax was ₹5.48 crores, marking a quarter-over-quarter increase of 7.2% from ₹5.11 crores in Q2FY25. Year-over-year, the profit before tax surged by 82.7% from ₹3.00 crores in Q3FY24. However, the profit after tax for Q3FY25 was ₹4.53 crores, which shows a decrease of 5.6% from the previous quarter's ₹4.80 crores, yet demonstrates a substantial year-over-year growth of 118.8% from ₹2.07 crores in Q3FY24. The earnings per share for Q3FY25 were ₹2.10, slightly down by 4.5% from ₹2.20 in Q2FY25, but reflecting a significant increase of 110.0% from ₹1.00 in Q3FY24.
Operating Metrics
The financial data reveals that Sakar Healthcare Ltd's total expenses for Q3FY25 were ₹38.19 crores. This represents a marginal increase of 0.4% compared to the previous quarter's expenses of ₹38.04 crores. Year-over-year, the total expenses rose by 10.9% from ₹34.45 crores in Q3FY24. The tax expenses for Q3FY25 were ₹0.94 crores, showing a substantial quarter-over-quarter increase of 203.2% from ₹0.31 crores in Q2FY25 and a slight year-over-year increase of 1.1% from ₹0.93 crores in Q3FY24. These metrics reflect the company's operational cost management and tax obligations during the period under review.
